- Record: found
- Abstract: found
- Article: not found
Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.
Mark G Kris
1 ,
Ronald B Natale ,
Roy S Herbst ,
Thomas J Lynch ,
Diane Prager ,
Chandra P Belani ,
Joan H Schiller ,
Karen Kelly ,
Harris Spiridonidis ,
Alan Sandler ,
Kathy S Albain ,
David Cella ,
Michael K Wolf ,
Steven D Averbuch ,
Judith J Ochs ,
Andrea C Kay
Oct 22 2003
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
More persons in the United States die from non-small cell lung cancer (NSCLC) than from breast, colorectal, and prostate cancer combined. In preclinical testing, oral gefitinib inhibited the growth of NSCLC tumors that express the epidermal growth factor receptor (EGFR), a mediator of cell signaling, and phase 1 trials have demonstrated that a fraction of patients with NSCLC progressing after chemotherapy experience both a decrease in lung cancer symptoms and radiographic tumor shrinkages with gefitinib.